COMBINING LOCALLY ADMINISTERED IPILIMUMAB WITH A PERSONALIZED NEOANTIGEN CANCER VACCINE TO IMPROVE T-CELL PRIMING AND ANTITUMOR IMMUNITY IN HIGH- RISK RENAL CELL CARCINOMA
$191,712FY2020Department of the ArmyDOD
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc.